Breast Cancer

Bruce Haffty, MD, MS, discusses the rationale for launching a clinical trial to assess the feasibility of preoperative radiation boost in patients with breast cancer.

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

Bruce Haffty, MD, MS, discusses the feasibility of utilizing preoperative radiation boost in patients with breast cancer based on initial results from a phase 2 trial.

Administration of stereotactic ablative body radiotherapy to oligoprogressive lesions delayed a change in systemic therapy in patients with estrogen receptor–positive/HER2-negative breast cancer enrolled to the prospective phase 2 AVATAR trial.

Treatment with reduced-dose or partial-breast radiotherapy sustained long-term safety and elicited similar rates of ipsilateral breast tumor relapse compared with whole-breast radiotherapy in patients with early-stage breast cancer.

Asal Rahimi, MD, MS, discusses initial efficacy results from the expanded cohort of a phase 1 dose-escalation study (NCT04040569) evaluating pre-operative, single fraction stereotactic ablative radiation in early-stage, hormone receptor–positive breast cancer.

Ablative preoperative stereotactic partial breast irradiation plus endocrine therapy was safe at a single fraction of 34 Gy and generated pathological complete responses and near complete responses in patients with early-stage, estrogen receptor-positive breast cancer.

Elizabeth Diaz, PA-C, details how she approaches adverse event management in patients undergoing treatment for HR+/HER2- metastatic breast cancer.

Dr Virginia Kaklamani explains how she selects among the available treatment regimens for her patients with HR+/HER2= metastatic breast cancer.

Patients with breast cancer who received hypofractionated postmastectomy radiotherapy experienced similar toxicities vs those who received conventionally fractionated postmastectomy radiotherapy, according to a presentation shared at the 2023 American Society for Radiation Oncology Annual Meeting.

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a PARP inhibitor.

Wesley J. Talcott, MD, MBA, discusses the importance of de-escalating therapy in patients with breast cancer, highlighting use of personalized treatment approaches.

Jairam Krishnamurthy, MD, FACP, highlights the benefits of neoadjuvant therapy in early-stage HER2-positive breast cancer, treatment considerations for patients with HER2-negative disease who have progressed on an initial CDK4/6 inhibitor, and ongoing research that may address unmet needs in the field.

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, Diaz review the available safety and efficacy data from the TROPiCS-02 trial on the use of antibody drug conjugate sacituzumab govitecan for the treatment of HR+/HER2- metastatic breast cancer.

Experts debate the utility of surgery on the primary tumor in patients with novel metastatic HR+/HER- breast cancer.

Virginia Kaklamani, MD, presents the case of a 56-year-old postmenopausal woman diagnosed with ER+/HER2- metastatic breast cancer for discussion.

Ezra Rosen, MD, PhD, highlights the early-phase investigation of zotatifin in estrogen receptor-positive metastatic breast cancer, explains the agent’s unique mechanism of action as well as its efficacy and safety in a heavily pretreated population, and underscores the need for improved sequencing of the myriad of treatment options in the post–CDK4/6 inhibitor space.

Judy C. Boughey, MD, discusses key characteristics that define the ideal population for surgical de-escalation among patients with breast cancer.

Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with inoperable or metastatic hormone receptor–positive, HER2-low or HER2-negative breast cancer.

Francisco J. Esteva, MD, PhD, discusses the use of CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

The European Commission has approved elacestrant for the treatment of postmenopausal women and men with estrogen receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least 1 line of endocrine therapy including a CDK4/6 inhibitor.